Literature DB >> 22378065

Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis.

Marco Trerotola1, Jing Li, Saverio Alberti, Lucia R Languino.   

Abstract

Trop-2 is a transmembrane glycoprotein upregulated in several human carcinomas, including prostate cancer (PrCa). Trop-2 has been suggested to regulate cell-cell adhesion, given its high homology with the other member of the Trop family, Trop-1/EpCAM, and its ability to bind the tight junction proteins claudin-1 and claudin-7. However, a role for Trop-2 in cell adhesion to the extracellular matrix has never been postulated. Here, we show for the first time that Trop-2 expression in PrCa cells correlates with their aggressiveness. Using either shRNA-mediated silencing of Trop-2 in cells that endogenously express it, or ectopic expression of Trop-2 in cells that do not express it, we show that Trop-2 inhibits PrCa cell adhesion to fibronectin (FN). In contrast, expression of another transmembrane receptor, α(v) β(5) integrin, does not affect cell adhesion to this ligand. We find that Trop-2 does not modulate either protein or activation levels of the prominent FN receptors, β(1) integrins, but acts through increasing β(1) association with the adaptor molecule RACK1 and redistribution of RACK1 to the cell membrane. As a result of Trop-2 expression, we also observe activation of Src and FAK, known to occur upon β(1) -RACK1 interaction. These enhanced Src and FAK activities are not mediated by changes in either the activity of IGF-IR, which is known to bind RACK1, or IGF-IR's ability to associate with β(1) integrins. In summary, our data demonstrate that the transmembrane receptor Trop-2 is a regulator of PrCa cell adhesion to FN through activation of the β(1) integrin-RACK1-FAK-Src signaling axis.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378065      PMCID: PMC3369113          DOI: 10.1002/jcp.24074

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  65 in total

Review 1.  Integrin-regulated FAK-Src signaling in normal and cancer cells.

Authors:  Satyajit K Mitra; David D Schlaepfer
Journal:  Curr Opin Cell Biol       Date:  2006-08-17       Impact factor: 8.382

Review 2.  Fibronectin and its integrin receptors in cancer.

Authors:  E Ruoslahti
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

3.  Rack1, a receptor for activated protein kinase C, interacts with integrin beta subunit.

Authors:  J Liliental; D D Chang
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

4.  PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion.

Authors:  Claire M Wells; Andrew D Whale; Maddy Parsons; John R W Masters; Gareth E Jones
Journal:  J Cell Sci       Date:  2010-04-20       Impact factor: 5.285

5.  A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity.

Authors:  Bryan Serrels; Emma Sandilands; Alan Serrels; George Baillie; Miles D Houslay; Valerie G Brunton; Marta Canel; Laura M Machesky; Kurt I Anderson; Margaret C Frame
Journal:  Curr Biol       Date:  2010-05-20       Impact factor: 10.834

6.  beta1 integrin cytoplasmic domain residues selectively modulate fibronectin matrix assembly and cell spreading through talin and Akt-1.

Authors:  J Angelo Green; Allison L Berrier; Roumen Pankov; Kenneth M Yamada
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

7.  Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas.

Authors:  M Fornaro; R Dell'Arciprete; M Stella; C Bucci; M Nutini; M G Capri; S Alberti
Journal:  Int J Cancer       Date:  1995-09-04       Impact factor: 7.396

8.  Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover.

Authors:  X D Ren; W B Kiosses; D J Sieg; C A Otey; D D Schlaepfer; M A Schwartz
Journal:  J Cell Sci       Date:  2000-10       Impact factor: 5.285

9.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

10.  Integrin-mediated signals regulated by members of the rho family of GTPases.

Authors:  E A Clark; W G King; J S Brugge; M Symons; R O Hynes
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539

View more
  23 in total

1.  Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling.

Authors:  Tanya Stoyanova; Andrew S Goldstein; Houjian Cai; Justin M Drake; Jiaoti Huang; Owen N Witte
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

2.  PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression.

Authors:  Leslie Ann Caromile; Linda H Shapiro
Journal:  Mol Cell Oncol       Date:  2017-04-28

3.  PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.

Authors:  Leslie Ann Caromile; Kristina Dortche; M Mamunur Rahman; Christina L Grant; Christopher Stoddard; Fernando A Ferrer; Linda H Shapiro
Journal:  Sci Signal       Date:  2017-03-14       Impact factor: 8.192

4.  The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.

Authors:  Michelle Shen; Shiqin Liu; Tanya Stoyanova
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

5.  Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.

Authors:  Jing Zhu; Wenwen Wu; Yukiko Togashi; Naoe Taira Nihira; Yoshikazu Johmura; Dajiang Zhu; Makoto Nakanishi; Yasuo Miyoshi; Tomohiko Ohta
Journal:  Breast Cancer       Date:  2022-07-27       Impact factor: 3.307

6.  ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2.

Authors:  Kerstin Huebner; Katharina Erlenbach-Wuensch; Jan Prochazka; Ilir Sheraj; Chuanpit Hampel; Blanka Mrazkova; Tereza Michalcikova; Jolana Tureckova; Veronika Iatsiuk; Anne Weissmann; Fulvia Ferrazzi; Philipp Kunze; Enise Nalli; Elisabeth Sammer; Annemarie Gehring; Marie M Cheema; Markus Eckstein; Eva-Maria Paap; Agnes Soederberg; Corinna Fischer; Sushmita Paul; Vijayalakshmi Mahadevan; Benardina Ndreshkjana; Melanie A Meier; Susanne Muehlich; Carol I Geppert; Susanne Merkel; Robert Grutzmann; Adriana Roehe; Sreeparna Banerjee; Arndt Hartmann; Radislav Sedlacek; Regine Schneider-Stock
Journal:  Cell Mol Life Sci       Date:  2022-07-15       Impact factor: 9.207

7.  Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion.

Authors:  Marco Trerotola; Saverio Alberti; Emanuela Guerra; Valeria Relli; Martina Ceci; Romina Tripaldi; Pasquale Simeone; Anna Laura Aloisi; Ludovica Pantalone; Rossana La Sorda; Rossano Lattanzio; Andrea Sacchetti; Kristina Havas; Simone Guarnieri; Daniele Vergara; Isabelle Fournier; Michel Salzet; Nicola Tinari; Mauro Piantelli
Journal:  Oncogene       Date:  2022-02-07       Impact factor: 8.756

Review 8.  Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.

Authors:  Parham Jabbarzadeh Kaboli; Shima Shabani; Sagar Sharma; Minoo Partovi Nasr; Hirohito Yamaguchi; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

9.  Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions.

Authors:  Marco Trerotola; Danielle L Jernigan; Qin Liu; Javed Siddiqui; Alessandro Fatatis; Lucia R Languino
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

10.  The cytosolic tail of the tumor marker protein Trop2--a structural switch triggered by phosphorylation.

Authors:  Miha Pavšič; Gregor Ilc; Tilen Vidmar; Janez Plavec; Brigita Lenarčič
Journal:  Sci Rep       Date:  2015-05-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.